Kalaris Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$44.3MTTM through 30 Jun 2026
Free Cash Flow -$41.2MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-65.3%ROE
-40.8%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio12.19x
Net Debt-$97.2Mnet cash position
Cash & Equivalents$43.2M
Quality Metrics
Altman Z-Score-1.99
Piotroski F-Score2 / 9
Earnings-Beat Rate50.0%
Multi-Year Trend
RevenueFY2019: $165K
Diluted EPS-$1.90TTMFY2025: $-2.85
Dividend
No dividend
Capital Allocation
R&D Spend$32.9M
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Biotechnology R&D | $0 | View detailsPreliminary data from the Phase 1b/2 study is anticipated in the first half of 2027, with planned Phase 3 clinical trials targeted to start by year-end 2027. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.